Analytical Platforms For Supporting Biodistribution Studies For AAV Gene Therapy

Analytical Consideration For Supporting Biodistribution Studies For AAV Gene Therapy

The biodistribution studies should be designed to answer the following questions

Profiling and quantity of the DNA/RNA of the gene therapy products in the different tissues
Expression and profiling of the target RNA gene or protein products in different tissues

Profiling and quantity of the DNA/RNA of the gene therapy products in the different tissues

Profiling and quantification of the DNA/RNA of the gene therapy products and biofluids are the primary object of the BD studies. These data provides the selective tropism of the AAV WT, serotypes and AAV variants to the different tissues. It has become even more important as there are increased efforts to identify novel AAVs with improved selective tropism and low immunogenicity. Both screening of natural variants and capsid engineering are extensively employed.

Currently, real-time quantitative polymerase chain reaction (qPCR) is considered the ‘gold standard’ for measurement of specific DNA (or, with a reverse transcription step, RNA as well) presence in tissues/biofluids. Digital droplet PCR is an emerging platform for these measurement. Quantification of nucleic acid sequences is important for assessing the relative amount of genetic material from a GT product and determining the kinetics of its accumulation or decay. The quantitative methods should be sufficiently sensitive with acceptable reproducibility.

Expression and profiling of the target RNA gene or protein products in different tissues

In addition of tissue specific tropism of AAV vectors, the tissue specific promoters are engineered to drive the selective expression of the target tissues. For example, albumin promoter or ApoE promoter are used to drive expression in the liver. In these cases, quantitation of the target RNA and proteins provide addition information of the selective expression. It helps identify differential expression of genes in intended vs unintended tissues and evaluate the safety risk and benefit. This also help tease out the correlation of presence of DNA/RNA of gene therapy with the gene expression.

The methods for detection/quantitation of RNA/proteins include: enzyme-linked immunosorbent assay (ELISA); immunohistochemistry (IHC); western blot; in situ hybridisation (ISH); digital PCR; flow cytometry; various in vivo and ex vivo imaging techniques; and other evolving technologies.

The details on quantitation methods and case studies are provided in the link below

Real Time PCR
Digital Droplet PCR
Enzyme Linked Immunosorbent Assay
Western Blot
In-Situ Hybridization
Flow Cytometry

Human Genome Editing: FDA Draft Guidance Summary

Consideration for Developing Gene Editing Product 1. Genome Editing Methods: Genome editing can be achieved through nuclease-dependent or nuclease-independent methods. Nuclease-dependent methods involve introducing site-specific breaks in DNA using technologies like zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), modified-homing endonucleases, and CRISPR-associated (Cas) nucleases. These breaks can lead to modification of the DNA sequence at the cleavage site. Nuclease-independent methods can change DNA sequences without cleaving the DNA and include techniques like base editing and synthetic triplex-forming peptide nucleic acids. The choice of GE technology should consider factors such as the mechanism of action, the ability to target specific DNA sequences, and the potential to optimize components for efficiency, specificity, or stability. 2. Type and Degree of Genomic Modification: Different GE approaches rely on DNA repair pathways such as ho

Human Gene Therapy for Neurodegenerative Diseases: FDA Guidance Summary

Neurodegenerative diseases are a diverse group of disorders characterized by the progressive degeneration of the central or peripheral nervous system, and they can have various causes and clinical characteristics. This guidance document is a resource for sponsors on different aspects of product development, preclinical testing, and clinical trial design. It acknowledges the unique challenges and considerations associated with developing GT products for such complex and varied diseases. Below are the key summaries from the guidance. CONSIDERATIONS FOR CHEMISTRY, MANUFACTURING AND CONTROLS (CMC) The considerations for Chemistry, Manufacturing, and Controls (CMC) when developing gene therapy (GT) products for the treatment of neurodegenerative diseases are crucial for ensuring the safety and efficacy of these advanced therapies. Here, we will elaborate on the specific CMC considerations outlined in your text: Route of Administration and Product Volume: Neurodegenerative diseases often r

Cellular & Gene Therapy Guidances (Food and Drug Administration)

Studying Multiple Versions of a Cellular or Gene Therapy Product in an Early-Phase Clinical Trial; Draft Guidance for Industry 11/2022 Human Gene Therapy for Neurodegenerative Diseases; Guidance for Industry 10/2022 Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products; Draft Guidance for Industry 3/2022 Human Gene Therapy Products Incorporating Human Genome Editing; Draft Guidance for Industry 3/2022 Interpreting Sameness of Gene Therapy Products Under the Orphan Drug Regulations; Guidance for Industry 9/2021 Manufacturing Considerations for Licensed and Investigational Cellular and Gene Therapy Products During COVID-19 Public Health Emergency; Guidance for Industry 1/2021 Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs); Guidance for Industry 1/2020 Long Term Follow-up After Administration of Human Gene Therapy Products; Guidance for Industry 1/2020 Testing of Retroviral Vecto

Stem loop RT-PCR for Detection of siRNA in Animal Tissues

Step Loop RT-PCR for Detection of Small Interfering RNA (siRNA) The recent publications described a novel used the novel method for the detection of siRNAs using a TaqMan®-based approach. This approach utilizes similar strategy that has been used for microRNA detection. The approach is illustrated in below. In brief, the RT step occurs in the presence of a stem-loop RT primer that is complementary to the last 6–10 bases of the 3′ end of the antisense strand of the target siRNA. The stem-loop primer contains an additional universal sequence at the 5′ end that facilitates a TaqMan-based detection strategy in the subsequent qPCR step. As in the case of microRNA, the forward primer for qPCR is sequence-specific for the target siRNA. For sequence compositions that yield a low predicted melting temperature (Tm), the forward primer is designed as a tailed primer to help increase Tm. Stem Loop PCR for SiRNA Detection Step 1: Preparation of liver and plasma samples for the quantification of si

Engineering AAV vectors for enhanced safety profiles

Engineering AAV vectors for enhanced safety profiles involves multiple strategies at both the vector genome and capsid levels. Here is a breakdown of these strategies: Vector Genome Level: Modifying Vector Genome Sequences: Scientists modify AAV vector genomes by adding, mutating, or deleting specific sequences. For example, self-complementary AAV (scAAV) vectors are designed by deleting key signals from the second inverted terminal repeat (ITR), allowing for more efficient genome replication. Codon Optimization: Optimizing the codon usage of the transgene can enhance its expression efficiency. Promoter and PolyA Sequence Selection: Careful selection and manipulation of promoter and polyadenylation (polyA) sequences can influence transgene expression and tissue specificity. Capsid Engineering: Capsid engineering strategies can be categorized into four main categories: Directed Evolution: This approach involves creating capsid mutant libraries using error-prone PCR or introducing pepti

Cell And Gene Therapy: Research, Development & Regulatory Guidance

Search This Blog